Navigation Links
Newly Published Study Results Showed That Two Mealtime Insulin Dosing Algorithms Were Effective for Patients with Type 2 Diabetes
Date:7/22/2008

to help manage the potential risks that come with prolonged hyperglycemia," said Dr. Bergenstal. "The Adjust to Target trial demonstrated that basal-bolus insulin therapy may be an effective option for the many people with type 2 diabetes who are not achieving glycemic targets with their current insulin regimen."

About the Trial

Study participants were 28-71 years old, had type 2 diabetes for greater than or equal to 6 months and mean +/- SD A1C values of 8.1 +/- 0.9% (Simplified Algorithm) and 8.3 +/- 0.9% (Carb Counting Algorithm) at screening. They had taken greater than or equal to 2 insulin injections/day (36 percent on 2 injections, 64 percent on more than 2 injections) +/- metformin (one-third were on metformin), for greater than or equal to 3 months before study entry. Upon entry into the study, 37 percent were using Lantus(R) and at least one injection of a rapid-acting insulin analog, 36 percent were using a pre-mixed insulin and the remainder were on a combination of various other diabetes treatment regimens.

About Diabetes

Diabetes is a chronic, widespread condition in which the body does not produce or properly use insulin -- the hormone needed to transport glucose (sugar) from the blood into the cells of the body for energy. More than 230 million people worldwide are living with the disease and this number is expected to rise to a staggering 350 million within 20 years. It is estimated more than 20 million Americans have diabetes, including an estimated 6.2 million who remain undiagnosed.

At the same time, more than 40 percent of those diagnosed are not achieving the blood sugar control target of A1C <7 percent recommended by the American Diabetes Association (ADA). The A1C test measures average blood glucose levels over a two- to three-month period.

About sanofi-aventis

Sanofi-aventis, a leading global pharmaceutical company, discovers, develops and distributes therapeutic solutions to improve the live
'/>"/>

SOURCE sanofi-aventis
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Millennium Initiates Clinical Trial to EVOLVE the Treatment of Patients with Newly Diagnosed Multiple Myeloma
2. Sixty-One Percent of Newly Diagnosed Parkinsons Disease Patients Do Not Receive Any Drug Treatment in the First Year of Diagnosis
3. Phase III Clinical Trial in Newly Diagnosed Multiple Myeloma Stopped Early Due to Highly Significant Efficacy Advantage of VELCADE(R) (Bortezomib) for Injection Based Therapy Across All Endpoints
4. Newly Published Phase II Study Shows the Investigational Drug Vandetanib Prolongs Progression-Free Survival in Patients with Advanced Non-Small Cell Lung Cancer (NSCLC)
5. New Data to Support VELCADE(R) (Bortezomib) For Injection Based Therapies as Setting New Standards in The Care of Newly Diagnosed Patients With Multiple Myeloma
6. Newly Approved HIV Drug Shows Great Promise
7. New Data Support High Complete Remission Rates With VELCADE(R) (Bortezomib) for Injection Based Therapies in Patients With Newly Diagnosed Multiple Myeloma
8. VELCADE(R) (Bortezomib) for Injection Based Treatment Delivers Impressive Complete Response and Survival in Patients With Newly Diagnosed Multiple Myeloma
9. Multiple Clinical Trials of VELCADE(R) (Bortezomib) for Injection Based Therapies Demonstrate High Complete Remission Rates in Patients with Newly Diagnosed Multiple Myeloma
10. Newly Published Study Shows OPKOs siRNA Bevasiranib Is Taken Up by Target Tissues in the Eye
11. Positive Kuvan(TM) Pivotal Phase 3 Trial Results Published in The Lancet
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/27/2015)... Research and Markets ( http://www.researchandmarkets.com/research/t63pbj/medical_device ) has announced the ... Markets Seminar" conference to their offering. ... well established, the next growth area is ... with other countries in this region have all implemented, ... medical device regulations. This seminar will provide a comprehensive ...
(Date:7/27/2015)... and MENLO PARK, Calif. ... Pharmaceuticals, Inc. (OTCQX: DMPI) ("DelMar" and the ... commercializing proven cancer therapies in new orphan drug ... from institutional and accredited investors for a registered ... common stock and 3.35 million common stock purchase ...
(Date:7/27/2015)... , July 27, 2015  Cardica, Inc. (Nasdaq: CRDC ... its fiscal fourth quarter ended June 30, 2015, on Thursday, ... host a conference call at 4:30 p.m. Eastern Time to ... company,s business. Conference Call Details To access ... p.m. Eastern Time via phone, please dial 877-703-6106 from ...
Breaking Medicine Technology:Medical Device Regulation in Asia/Pacific Markets Seminar: London, UK - 21st, 22nd of September 2015 2DelMar Pharmaceuticals Announces Financing Update and Initial Subscriptions of $2.0 million in Registered Direct Offering 2DelMar Pharmaceuticals Announces Financing Update and Initial Subscriptions of $2.0 million in Registered Direct Offering 3Cardica To Announce Fiscal 2015 Fourth Quarter Financial Results On Thursday, August 6, 2015 2
... Candidate to Enter Clinical ... Studies in ... today it has initiated a Phase I clinical study of a ... safety, tolerability, and systemic pharmacokinetics of a topical,patch formulation of diclofenac ...
... Antisense Drug Targeting Glucagon Receptor for Treatment ... of Type 2 ... ) announced today it has earned $5,million from Ortho-McNeil, Inc. (OMI), a ... Phase 1,clinical trial of ISIS 325568. The collaboration between Isis and ...
Cached Medicine Technology:Cerimon Pharmaceuticals Initiates Phase I Clinical Study of Topical Diclofenac Sodium Patch 2Cerimon Pharmaceuticals Initiates Phase I Clinical Study of Topical Diclofenac Sodium Patch 3Isis Earns $5 Million Milestone Payment From Ortho-McNeil, Inc. for Initiation of Phase 1 Study of ISIS 325568 2Isis Earns $5 Million Milestone Payment From Ortho-McNeil, Inc. for Initiation of Phase 1 Study of ISIS 325568 3
(Date:7/27/2015)... ... 27, 2015 , ... On July 14, 2015, Harper’s Bazaar Magazine in an ... skin issues such as stretch marks , fine lines , and ... treatment options listed include lasers, ultrasound, radio frequency, Botox, and dermal fillers. It is ...
(Date:7/27/2015)... , ... July 27, 2015 , ... Eugene Batelli, D.P.M., ... accomplished athlete. “The patient is high-end athlete, whose accomplishments include running in 27 ... of Achilles tendon pain, which was diagnosed as tendinitis. I did an ultrasound ...
(Date:7/27/2015)... ... July 27, 2015 , ... The Maricopa Community Colleges today ... foster care system to get into and complete college. , The “Bridging Success ... an event today with partners from across the valley. , The initiative advisory board ...
(Date:7/27/2015)... New York, NY (PRWEB) , ... July 27, 2015 , ... ... North American tour. He will be performing for one additional night at each ... can add promo/coupon code DAVID-GILMOUR-2016 for added savings. , David Gilmour’s 2016 North America ...
(Date:7/27/2015)... , ... July 27, 2015 ... ... Global Calcium Propionate industry is a professional and in-depth research report. The ... industry chain structure, international market analysis etc. This report covers the global ...
Breaking Medicine News(10 mins):Health News:The Latest Treatment Options for Seven Common Skin Issues 2Health News:NJ Top Docs Presents, Dr. Eugene Batelli of Metropolitan Ankle & Foot Care Specialists 2Health News:NJ Top Docs Presents, Dr. Eugene Batelli of Metropolitan Ankle & Foot Care Specialists 3Health News:Maricopa Community Colleges Launch Program To Help Youth In Foster Care Finish College 2Health News:Maricopa Community Colleges Launch Program To Help Youth In Foster Care Finish College 3Health News:Cheap David Gilmour Tickets at Madison Square Garden (MSG), Air Canada Center, United Center and Hollywood Bowl: Additional Dates for David Gilmour Go On Sale Today 2Health News:Calcium Propionate Market Global Suppliers and Manufacture Analysis 2Health News:Calcium Propionate Market Global Suppliers and Manufacture Analysis 3
... cold virus to deliver pluripotent cells circumvents safety concerns, ... Researchers report that they have sidestepped a major technical ... adult cells. , A team of Boston scientists developed ... -- which are functionally similar to embryonic stem cells, ...
... to Eat Right, Move More and ... Milk Their Diets, NASHVILLE, Tenn., ... of different fad diets -- which seem to go in,and out of fashion ... three Americans -- including 27 percent of,Nashville residents -- remain overweight or obese., ...
... You Pink" campaign warns of "pinkwashing"., SAN ... respected watchdog of the breast cancer movement - ... Pink" campaign. The annual consumer,education campaign offers tips ... ( http://www.thinkbeforeyoupink.org ), This year,s campaign warns ...
... PHILADELPHIA, Sept. 25 The Council on Compulsive,Gambling of ... Systems Inc., and the Western Psychiatric Institute and,Clinic, our ... East Holiday Inn at 4751 Linden Road will host ... The Conference will be opened by,Tom Wolf, Secretary of ...
... 25 Sept. 26, 2008, marks the,100th anniversary ... 1908,Jersey City, N.J., was the first city in ... water. Since then, incidences of,waterborne diseases have plummeted, ... Director Gary Zimmerman,offers the following comments on behalf ...
... Employees Proves Worksite Wellness Programs Work, DALLAS, Sept. ... been recognized by the American Heart Association,s,Start! Fit-Friendly Companies ... place -- a 20 percent increase over last year., ... to get,Americans walking. Most adult Americans spend a majority ...
Cached Medicine News:Health News:Researchers Report Stem Cell Advance 2Health News:Researchers Report Stem Cell Advance 3Health News:Researchers Report Stem Cell Advance 4Health News:Message to Tennessee Residents: Forgo Fad Dieting and Join the Campaign for Healthy Weight 2Health News:Message to Tennessee Residents: Forgo Fad Dieting and Join the Campaign for Healthy Weight 3Health News:Breast Cancer Action Targets Yoplait in 'Think Before You Pink' Campaign; Calls for Yogurt Without Artificial Hormones 2Health News:Statewide Gambling Conference -- Series of 'Firsts' -- Begins 9-30-08 2Health News:AWWA Marks 100th Anniversary of Chlorine Disinfection 2Health News:American Heart Association Announces Start! Fit-Friendly Companies 2Health News:American Heart Association Announces Start! Fit-Friendly Companies 3
The Natural-Hip combines the surgical simplicity of a straight stem with many of the best features of an anatomic stem....
The Natural-Hip combines the surgical simplicity of a straight stem with many of the best features of an anatomic stem....
The Perfecta IMC Stems, manufactured from forged cobalt- chrome, are specifically designed for cemented femoral stem arthroplasty....
Simple straight stem design for the low-demand patient....
Medicine Products: